ABSTRACT
The most recent successful advances in lung cancer therapy have directly and increasingly focused on personalized tumor genetic/epigenetic/immunologic profiling, and the identification and development of novel pharmacologic agents aimed at those mutations [e.g., epidermal growth factor receptor (EGFR), Kristen rat sarcoma viral oncogene homolog (KRAS), anaplastic lymphoma kinase (ALK) and immunotherapy against programmed cell death protein 1 (PD-1) and its ligands] which have extended life and provided palliation for lung cancer-patients positive for these mutations. The objective of this study is to provide a review of the large number of drugs and their efficacy as of 2022, for lung cancer, but also introduce a novel treatment that has the potential, based on one controlled murine lung cancer study and 5 anecdotal human cases, that showed marked palliative and longevity benefits in very advanced lung cancer with no other treatment options, i.e., progesterone receptor (PR) antagonists targeting the immunosuppressive protein, the progesterone induced blocking factor (PIBF). Credibility, however, will only be provided when the efficacy can be demonstrated in a large series of lung cancer cases ideally with certain controls. Thus, the ultimate objective of the review is to interest oncologists with a large population of lung cancer patients to perform a well powered study to corroborate or refute the limited experience to date with PR antagonist therapy.
Subject(s)
Lung Neoplasms , Receptors, Progesterone , Animals , Humans , Mice , Immunotherapy , Lung Neoplasms/drug therapy , Lung Neoplasms/genetics , Progesterone , Receptors, Progesterone/antagonists & inhibitors , Steroids , Treatment OutcomeABSTRACT
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced cancers. However, activation of the immune system can occasionally cause life-threatening toxicity involving critical organs. Induction of immune-mediated toxicity is a significant concern for patients with thymic epithelial tumors (TETs) due to defects in immune tolerance. An increased risk of skeletal and cardiac muscle inflammation following treatment with ICIs is well recognized in patients with advanced TETs. However, uncommon musculoskeletal and rheumatic complications can also occur. The cases presented in this report highlight the spectrum of presentation of immune-mediated, joint-predominant musculoskeletal adverse events in patients with advanced TETs treated with ICIs, including polymyalgia rheumatica-like illness and inflammatory arthritis.
Subject(s)
Myositis , Neoplasms, Glandular and Epithelial , Neoplasms , Polymyalgia Rheumatica , Thymus Neoplasms , Humans , Immune Checkpoint Inhibitors , Immunotherapy/adverse effects , Myositis/chemically induced , Neoplasms/drug therapy , Neoplasms, Glandular and Epithelial/drug therapy , Polymyalgia Rheumatica/drug therapy , Polymyalgia Rheumatica/etiology , Thymus Neoplasms/drug therapyABSTRACT
PURPOSE: To examine the benefit of telehealth over current delivery options in oncology practices without genetic counselors. METHODS: Participants meeting cancer genetic testing guidelines were recruited to this multi-center, randomized trial comparing uptake of genetic services with remote services (telephone or videoconference) to usual care in six predominantly community practices without genetic counselors. The primary outcome was the composite uptake of genetic counseling or testing. Secondary outcomes compare telephone versus videoconference services. RESULTS: 147 participants enrolled and 119 were randomized. Eighty percent of participants in the telehealth arm had genetic services as compared to 16% in the usual care arm (OR 30.52, p < 0.001). Five genetic mutation carriers (6.7%) were identified in the telehealth arm, compared to none in the usual care arm. In secondary analyses, factors associated with uptake were lower anxiety (6.77 vs. 8.07, p = 0.04) and lower depression (3.38 vs. 5.06, p = 0.04) among those who had genetic services. There were no significant differences in change in cognitive or affective outcomes immediately post-counseling and at 6 and 12 months between telephone and videoconference arms. CONCLUSION: Telehealth increases uptake of genetic counseling and testing at oncology practices without genetic counselors and could significantly improve identification of genetic carriers and cancer prevention outcomes.
Subject(s)
Genetic Services/statistics & numerical data , Medical Oncology/statistics & numerical data , Telemedicine/statistics & numerical data , Anxiety/epidemiology , Counselors , Depression/epidemiology , Female , Genetic Carrier Screening/statistics & numerical data , Genetic Counseling/statistics & numerical data , Genetic Testing/statistics & numerical data , Humans , Male , Middle Aged , Mutation Rate , Socioeconomic Factors , Telemedicine/methods , Telephone/statistics & numerical data , Time Factors , Videoconferencing/statistics & numerical dataABSTRACT
BACKGROUND/AIM: It has been hypothesized that many, or even most cancers, utilize a unique immunomodulatory protein, called the progesterone induced blocking factor (PIBF) to allow spread of the cancer. Support for this concept has been provided by cancer cell line studies showing that PIBF is produced by these cancer cells and mifepristone suppresses this protein and inhibits proliferation of these cells. Furthermore, controlled murine studies with several spontaneous different types of cancer showed a clear beneficial effect of mifepristone over placebo control. Finally, there have been a variety of anecdotal reports showing efficacy of mifepristone in providing increased length and quality of life in patients with different types of advanced cancers. CASE REPORT: Single agent mifepristone was found to provide significant palliative benefit for a 51-year-old male whose metastatic advanced fibroblastic osteosarcoma progressed despite surgery, radiotherapy, multiagent chemotherapy, and targeted therapy. CONCLUSION: Thus, osteosarcoma can be added to the list of cancers, not necessarily associated with the classic nuclear progesterone receptor, that seem to respond to progesterone receptor antagonist therapy.
Subject(s)
Bone Neoplasms/drug therapy , Mifepristone/administration & dosage , Osteosarcoma/drug therapy , Palliative Care/methods , Administration, Oral , Bone Neoplasms/pathology , Cancer Pain/drug therapy , Humans , Male , Middle Aged , Neoplasm Metastasis , Osteosarcoma/pathology , Quality of Life , Tibia , Treatment OutcomeABSTRACT
BACKGROUND: There is evidence that a unique immunomodulatory protein, known as the progesterone induced blocking factor (PIBF), is utilized by a large variety of cancers to escape immune surveillance. Mifepristone, a progesterone receptor antagonist/modulator, anecdotally, has been found to increase both length and quality of life in many different types of advanced cancers. CASE REPORT: Though there was one previous case of pancreatic cancer that showed a significant reduction in pain for the one month she took mifepristone before changing to an experimental drug, the case presented here provided much greater evidence that this drug can markedly improve both length and quality of life, in at least some patients, with very advanced pancreatic cancer. CONCLUSION: It is hoped that this case report will influence others to prescribe mifepristone off-label and hopefully substantiate this finding of marked palliative benefit in the majority of a larger series of patients.
Subject(s)
Analgesics, Opioid/therapeutic use , Hormone Antagonists/therapeutic use , Mifepristone/therapeutic use , Morphine/therapeutic use , Pancreatic Neoplasms/drug therapy , Quality of Life/psychology , Analgesics, Opioid/pharmacology , Hormone Antagonists/pharmacology , Humans , Male , Middle Aged , Mifepristone/pharmacology , Morphine/pharmacology , Pancreatic Neoplasms/mortality , Pancreatic Neoplasms/pathology , Survival AnalysisABSTRACT
CASE REPORT: Case 1 of an investigator-initiated study using oral single agent mifepristone to halt stage IV non-small cell lung cancer whose tumor was devoid of any targeted markers has remained ECOG zero and in good health for over 3 years. Case 2, reported here, is a 68-year-old woman with stage IV non-small cell lung cancer whose tumor was positive for the programmed death ligand-1 (PD-L1) marker. Her cancer progressed despite treatment with a check-point inhibitor (nivolumab), besides 3 rounds of multi-agent chemotherapy. After 1 ½ years of treatment with single agent mifepristone, her cancer remains stable (even some tumor regression) and her quality of life is only impaired by her pre-existing chronic obstructive lung disease, not her cancer. CONCLUSION: Mifepristone therapy may provide a method to halt metastatic lung cancer positive for the PD-L1 marker when check-point inhibitors are no longer effective.